Stockscreener 앱 받기
9.17
0.55%
0.05
전일 마감가:
$9.12
열려 있는:
$9.12
하루 거래량:
1.44M
Relative Volume:
0.46
시가총액:
$1.23B
수익:
$24.30M
순이익/손실:
$-145.57M
주가수익비율:
-6.8947
EPS:
-1.33
순현금흐름:
$-149.17M
1주 성능:
-4.18%
1개월 성능:
+15.64%
6개월 성능:
+105.15%
1년 성능:
+177.04%
1일 변동 폭
$9.00
$9.34
1주일 범위
$8.88
$10.22
52주 변동 폭
$1.03
$11.20
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
TNGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
9.17 | 1.23B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Vivo Capital LLC Purchases Shares of 600,000 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by XTX Topco Ltd - MarketBeat
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32% - simplywall.st
Geode Capital Management LLC Grows Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
How interest rate cuts could boost Tango Therapeutics Inc. stockMarket Risk Analysis & Daily Profit Focused Screening - Newser
Stifel Initiates Coverage of Tango Therapeutics (TNGX) with Buy Recommendation - Nasdaq
Is Tango Therapeutics Inc. stock near bottom after declineJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target - Investing.com Nigeria
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target By Investing.com - Investing.com South Africa
Piper Sandler Healthcare Conference - marketscreener.com
Virtus Investment Advisers LLC Sells 38,979 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (TNGX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can Tango Therapeutics Stock Hold Up When Markets Turn? - Trefis
Retail Trends: How interest rate cuts could boost Tango Therapeutics Inc stockRecession Risk & Fast Exit Strategy with Risk Control - BỘ NỘI VỤ
Tango Therapeutics Inc trading resumes - MSN
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy - MSN
Tango Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Tango Therapeutics launches $100M at-the-market stock offering - MSN
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - MSN
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week HighTime to Buy? - MarketBeat
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Tango Therapeutics stock hits 52-week high at 9.7 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal TestingBuy (TNGX) - Seeking Alpha
Tango Therapeutics stock hits 52-week high at 9.7 USD - Investing.com India
Tango Therapeutics launches new $100 million at-the-market stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc files for mixed shelf offeringSEC filing - marketscreener.com
Tango Therapeutics files prospectus for resale of 1.7 million shares by selling stockholderSEC filing - marketscreener.com
Tango Therapeutics launches new $100 million at-the-market stock offering - Investing.com Nigeria
Tango Therapeutics Enters New Sales Agreement with Leerink - TipRanks
[S-3] Tango Therapeutics, Inc. Shelf Registration Statement | TNGX SEC FilingForm S-3 - Stock Titan
[8-K] Tango Therapeutics, Inc. Reports Material Event | TNGX SEC FilingForm 8-K - Stock Titan
Why Tango Therapeutics Inc. stock remains on watchlists2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Short interest data insights for Tango Therapeutics Inc.Weekly Trade Review & Accurate Intraday Trade Tips - newser.com
How analysts rate Tango Therapeutics Inc. stock todayWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
TNGX: Pivotal pancreatic cancer study advances, with strong combo data and cash runway into 2028 - TradingView
Will Tango Therapeutics Inc. stock benefit from automationForecast Cut & Short-Term Trading Alerts - newser.com
TNGX: Vopimetostat advances in pivotal and combo studies, with strong efficacy and cash runway into 2028 - TradingView
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
0.12%
자본화:
|
볼륨(24시간):